deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03373435

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia (PREVENT)

A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Sponsor: Eiger BioPharmaceuticals

Conditions Postbariatric Hypoglycemia
Interventions Placebo exendin 9-39
Updated 14 times since 2017 Last updated: Jun 30, 2022 Started: Mar 19, 2018 Primary completion: Jan 30, 2019 Completion: Mar 15, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Postbariatric Hypoglycemia, this trial is completed. The trial is conducted by Eiger BioPharmaceuticals and has accumulated 14 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Mar 2019 · 7 months · monthly snapshot~Mar 2019 – ~Mar 2020 · 12 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jul 2022 — Sep 2022 [monthly]

    Completed PHASE2

  5. Apr 2022 — Jul 2022 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  2. Mar 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Mar 2019 — Mar 2020 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Aug 2018 — Mar 2019 [monthly]

    Recruiting PHASE2

  5. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  6. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  7. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  8. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Dec 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eiger BioPharmaceuticals
Data source: Eiger BioPharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations